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Arūnas Ščiupokas, Liuda Brogienė and Dalia Skorupskienė
Abstract
In 1986, the World Health Organization (WHO) has published a document enti-
tled “A Declaration of the Rights of Patients with Chronic Cancer,” which says that 
according to the WHO, three-step analgesic ladder pain relief should be adequate 
for 70–90% of patients. However, despite increased attention on assessment and 
management, pain continues to be a prevalent symptom for patients with cancer. 
That is why refreshment of knowledge in cancer pain is necessary for every active 
practitioner. Broad overview of current understanding in cancer pain is presented 
in the chapter. Cancer pain syndromes are analyzed in between acute or chronic, 
and in among various causes occurred. Cancer pain assessment was presented with 
challenges meeting clinical practitioners. For cancer pain treatment, principles of 
multimodal approach are used. The pharmaceutical treatment presented in detail 
included rational use of opioids. Big attention is paid on palliative care of cancer 
pain patients and hospice-based palliative care model is presented too. New tech-
nologies of breakthrough cancer pain management are disclosed in detail including 
special questionnaire for patients. Cancer survivors’ pain treatment and general 
practitioner’s role among cancer pain problems are new topics presented in the 
chapter.
Keywords: cancer pain syndromes, assessment and treatment principles, multimodal 
approach, basic and breakthrough cancer pains, palliative care
1. Introduction
Cancer is diagnosed for more than 10 million people worldwide each year, and the 
illness of a malignant tumor is often associated with pain. The consequences of unre-
lieved cancer pain are devastating [1]. During the established diagnosis of cancer, the 
pain is present for 40% of tumor patients. The number increases up to 75–80% with 
the disease spread. About 4 million people in the world each day suffer from pain that 
comes due to oncological diseases, meaning that almost half of them do not receive 
proper treatment, and one-third live in severe or unbearable pain [2].
Despite increased attention on assessment and management, pain continues to 
be a prevalent symptom in patients with cancer. With reference to types of cancer, 
lower pain prevalence rates were demonstrated in prostate cancer compared to head 
and neck, lung, and breast cancer. Higher prevalence rates were seen in stud ies 
from Asia compared to Europe, in studies that used point or week prevalence rates 
compared to recall periods of a month or year [3].
Over the past few decades, we succeeded a better understanding of mecha-
nisms underlying cancer pain, new developments achieved in pharmacologic 
cancer pain management, and increase in global opioid consumption becoming 
evident. Nevertheless, one-third of the patients worldwide still did not receive pain 
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medication proportional to their pain intensity levels [4]. Data from Asia and North 
America revealed comparable prevalence rates, which imply that opioid availability 
alone is not an explanation for the high prevalence rates [3]. Even after implementa-
tion into clinical practice of rapid release opioids (ROOs), which provide faster 
relief than immediate-release preparations of other opioids, the prevalence of 
breakthrough pain is still 59% [5]. All these mean the importance of skilled use 
of opioid analgesics in the relief of cancer pain but also acknowledge the lack of 
evidence to support clinical practice and guidelines, which in turn causes recom-
mendations in practice guidelines to be based on expert consensus.
In 1986, the World Health Organization (WHO) has published a document 
entitled “A Declaration of the Rights of Patients with Chronic Cancer.” According 
to the WHO three-step analgesic ladder, in combination with appropriate dosage 
guidelines, pain relief should be adequate for 70–90% of patients. A systematic 
review on pain relief based on the WHO ladder, 20 years after its introduction, 
demonstrated adequate pain relief in 45–100% of patients [6, 7]. Among subjects 
of debates to improve the analgesic ladder the benefit of paracetamol (acetamino-
phen) with Step III opioids for which the evidence is “weak if any,” as well as 
the use of adjuvant analgesics for which outcomes are generally modest [8]. On 
the other hand, not only drugs are a guarantee of success in the cancer pain. It 
is widely accepted that a biopsychosocial approach in assessment and manage-
ment is needed for treatment of pain in patients with cancer. Cicely Saunders 
elaborated on the concept of “total pain,” stating that pain is not purely a physical 
experience but involves various other components of human functioning includ-
ing personality, mood, behavior, and social relations. A systematic review has 
identified an association between psychological distress, lack of social support, 
and cancer pain [9].
Different barriers have been acknowledged in relation to adequate pain 
management in patients with cancer. One of the most important reasons is lack 
of knowledge regarding the assessment and management of cancer pain. Health 
professionals are cautious when prescribing opioids because of fear of adverse 
effects, tolerance, and addiction. Otherwise, patients struggle with misconcep-
tions about analgesic use, concerns about pain communication, and a belief that 
pain is inevitable and uncontrollable [10]. All reasons for the lack of adequate 
pain control are varied: (a) personal—fear of drug addiction, (b) legal issues 
by issuing a higher dose of these medicines, (c) material—with regard to the 
price and quantity of medicinal products, (d) organizational—regular supply 
and storage of medicines, (e) psychological—the conviction of the patient or 
his family members that narcotic analgesics can be used only in the last stages 
of the illness, (f) causes of medical staff in the absence of sufficient knowledge 
of analgesia and the principles for its administration, and (g) poor adherence to 
pain medication and poor pain relief, which appear to be more country-specific 
problems [11].
2. Cancer pain syndromes
Pain is an unpleasant sensory and emotional experience associated with actual 
or potential tissue damage, or described in terms of such damage. Pain is always 
subjective [the International Association for the Study of Pain (IASP)]. Cancer-
induced pain may be acute or chronic. Cancer-induced pain may be nociceptive or 
neuropathic or psychogenic, but often it is mixed because there are several causes 
causing it to occur. The main (basic) is constant pain of controlled intensity. A 
breakthrough pain occurs when a basic pain is controlled. Breakthrough pain is a 
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temporary exacerbation with high intensity pain, which is felt in patients whose 
basic pain was adequately treated with opioids [12].
Cancer pain is not a single entity. It incorporates a range of etiological, patho-
physiological, and anatomical subtypes, all requiring unique descriptive terminol-
ogy, assessment techniques, and treatment modalities [13]. Among patients with 
cancer, there is substantial heterogeneity in how pain is experienced and in how 
it appears. In many cases, the constellation of symptoms and signs can suggest a 
specific cancer pain syndrome [14]. The identification of such a syndrome may help 
to elucidate the etiology of the pain, direct the diagnostic evaluation, clarify the 
prognosis for the pain or the disease itself, and guide therapeutic intervention.
2.1 Acute pain syndromes
Most acute cancer pain syndromes are primary as related to a diagnostic test or 
treatment. However, some are secondary as they are disease related, such as pain due 
to acute hemorrhage into a tumor, bone pain from a pathologic fracture, etc. Although 
some tumor-related pains have an acute onset (as after pathological fracture), most 
of these will persist unless effective treatment for the underlying lesion is provided. 
Generally, acute cancer pain syndromes are divided: (1) directly related to cancer, (2) 
cancer diagnostics related, and (3) associated with antineoplastic treatments.
A clinical picture of directly related to various cancer syndromes depends on 
cancer’s etiology, location, surrounding tissues involved, growing speed, and other 
factors. Cancer-diagnostic-related syndromes also have miscellaneous presentation 
and can be presented as: (a) headache after lumbar puncture, (b) prostate pain 
after biopsy, (c) breast pain after mammography; (d) pain after any other interven-
tion, and some others. Acute pain associated with antineoplastic treatments can be 
presented as: (a) pain related to chemotherapy and (b) pain after radiotherapy [15].
Related to chemotherapy pain has various causes depending on an agent used, a 
method of inclusion into organism, etc. Most typical are intravenous infusion pain 
(due to venous spasm, chemical phlebitis, vesicant extravasation, and anthracycline-
associated flare), intraperitoneal chemotherapy pain (chemical serositis or infec-
tion), mucositis (due to cytotoxicity of cytarabine, doxorubicin, methotrexate, and 
others), painful peripheral neuropathy (toxicity associated with vinca alkaloids, cis-
platinum, oxaliplatin, and paclitaxel), headache (after intrathecal methotrexate), 
myalgias/arthralgias interferon induced, and others. Pain after radiotherapy can be 
incident pain precipitated by transport and positioning of the patient for radiother-
apy, or it can be caused by acute radiation toxicity. Most typical are: oropharyngeal 
mucositis, early-onset brachial plexopathy, subacute radiation myelopathy, radiation 
enteritis and proctitis, and others. Some more acute cancer pain syndromes can be 
related to infection (herpes zoster) or venous thrombotic events.
2.2 Chronic pain syndromes
Chronic cancer pain syndromes usually are directly related to the neoplasm itself 
or to an antineoplastic therapy. The classification is presented in Table 1 [16].
Bone metastases are the most common cause of chronic pain in cancer 
patients. Bone pain should be differentiated from non-neoplastic causes includ-
ing osteoporotic fractures (such as associated with multiple myeloma), focal 
osteonecrosis (due to chemotherapy or corticosteroids, or radiotherapy), and 
osteomalacia. Vertebrae are the most common sites of bony metastases pain. 
Typical locations are atlantoaxial destruction and odontoid fracture, C7–T1 
syndrome, and T12–L1 (thoracolumbar junction) syndrome. Epidural compres-
sion of the spinal cord or cauda equina is a common neurologic complication 
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of cancer. Breast, lung, and prostate cancers each account for 20–25% of events 
[17]. And back pain is the initial symptom in almost all patients with epidural 
compression. The pelvis and hip are also common sites of metastatic involve-
ment. Lesions may involve any of the three anatomic regions of the pelvis 
(ischiopubic, iliosacral, or periacetabular), the hip joint itself, or the proximal 
femur [18]. Leptomeningeal metastases, which are characterized by diffuse or 
multifocal involvement of the subarachnoid space by metastatic tumor, occur 
in 1–8% in patients with systemic cancer [19]. The most common presenting 
symptoms are headache, cranial nerve palsies, and radicular pain in the low 
back and buttocks. Gadolinium-enhanced MRI imaging of the neuroaxis is the 
investigation of choice when leptomeningeal metastases are suspected. Base of 
skull metastases can be presented with various syndromes: orbital syndrome, 
parasellar syndrome, middle cranial fossa syndrome, jugular foramen syn-
drome, trigeminal neuralgia, and others. Neuropathic pains can be presented 
as painful radiculopathy, postherpetic neuralgia, malignant brachial plexopa-
thy (lymphoma, beast, lung cancers). Brachial plexopathy also is typical for 
radiation-induced syndromes. Radiation changes in the skin and lymphoedema 
are commonly associated. Malignant lumbosacral plexopathy is most frequently 
associated with colorectal, cervical, breast cancers, sarcoma, and lymphoma 
[20]. Paraneoplastic painful peripheral neuropathy can be related to injury to the 
dorsal root ganglion (also known as subacute sensory neuronopathy or gangli-
onopathy) or injury to peripheral nerves [21]. Subacute sensory neuronopathy 
is usually associated with small cell carcinoma of the lung. Even in the absence 
Chronic cancer pain syndromes Clinical presentation
Tumor-related somatic pain syndromes Multifocal bone pain
Soft tissue pain
Tumor-related visceral pain syndromes
Tumor-related neuropathic pain Leptomeningeal metastases
Cranial neuralgias
Radiculopathies
Plexopathies
Peripheral mononeuropathies
Paraneoplastic syndromes
Headache
Pain related to antineoplastic treatments Chemotherapy-related neuropathy
Bone complications and glucocorticoids
Antiandrogens and gynecomastia
Postsurgical pain syndromes Pain and phantom sensation after amputation
Postradiation pain syndromes Plexopathies
Myelopathy
GI tract disorders
Lymphedema
Osteonecrosis
Table 1. 
The classification of cancer chronic pain syndromes.
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of involvement of the chest wall or parietal pleura, lung tumors can produce a 
visceral pain syndrome, being unilateral or bilateral (less common).
Most treatment-related pains are caused by tissue-damaging procedures. 
Chronic-treatment-related pain syndromes are associated with either a persistent 
nociceptive complication of an invasive treatment (such as a postsurgical abscess), 
or more commonly, neural injury. Toxic peripheral neuropathy, avascular (aseptic) 
necrosis of femoral, or humeral head are among most common treatment-related 
chronic cancer pain syndromes. Breast surgery pain syndromes are very prevalent, 
too. Chronic neuropathic pain of variable severity is common for those patients, and 
severity of pain is correlated positively with the number of lymph nodes removed 
[22] both with tumor location (upper outer quadrant of the breast).
3. Cancer pain assessment
Despite significant medical, pharmacological, and technological advances in 
the area of cancer pain assessment and management, up to 90% of patients with 
advanced cancer experience pain [23], which means careful pain assessment is 
essential for successful pain management. Cancer pain assessment is a complex 
undertaking. The evaluation begins with a thorough history of both the pain and 
the underlying malignancy as well as its treatment. A localization and intensity 
of pain have to be analyzed in detail, constantly indicating it in the diary. After 
initial treatment, the effect of treatment pain intensity is to be re-evaluated. 
Because of the potential impact of pain on quality of life, it is also essential to 
determine the adverse effects of pain on physical and psychosocial well-being, 
as well as the spiritual impact of the pain. Also, it is important to remember 
that cancer pain may linger after the cancer is removed (as examples, postmas-
tectomy, postamputation, or postthoracotomy syndrome), and this may have 
important psychological and spiritual impact. Other factors that may influence 
the pain experience should be overestimated and discussed with the patient and 
his family.
Current recommendations advise that pain severity should be assessed on an 
11-point numerical rating scale (NRS) (0–10), with more comprehensive tools 
including the Brief Pain Inventory (BPI) and McGill Short Form Questionnaire 
reserved for occasions when more detailed assessment is required [24, 25]. Newer 
tools including the Alberta Breakthrough Pain Assessment Tool, specifically 
designed for breakthrough pain, also could be used in the clinical trial setting [26].
3.1 Pain measurement scales
Numerical rating scale (NRS)—the intensity of pain is measured by asking the 
patient to select a number from 0 to 10 that describes the intensity of his pain: “0” 
means “no pain” and “10” means “unbearable pain.” The numbers are arranged in 
one line. This method is easily understood by many patients, eliminates linguistic 
and cultural barriers between the investigator and patient, and is most often recom-
mended for pain assessment. The lingual version of NRS can be easily adapted to 
ill patients who cannot write. In Verbal Rating Scale (VRS), patients are asked to 
choose the word best suited to describe their pain: no pain, mild pain, moderate 
pain, severe pain, and unbearable pain.
In Faces pain scale (FPS), five smileys are given, starting from a smiley face to 
the left (no pain) to a sad, and crying right (“unbearable pain”) (Figure 1). The 
patient points out the smile that most reflects the pain. The researcher compares the 
chosen smile with the expression of the patient’s face.
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These three pain scales (NRS, VRS, and FPS) are useful clinical tools to assess 
pain intensity if they are integrated in Table 1, which allows a comparative assess-
ment of the patient’s pain intensity [27].
In Visual analogue scale (VAS), patients are asked to pinpoint their pain in the 
10 cm section (in the straight line) as accurately as possible. The end of the left line 
indicates “no pain” and the right is “unbearable pain.” The method is widely used in 
scientific research, but not all patient groups are easy to understand.
Inferred pathophysiology or types of cancer pain (nociceptive/neuropathic) are 
also core in diagnostics, that is why neurological somatosensory examination using 
specific sensory stimuli tools (von Frey filament, brush, pin prick, hot/cold water 
tubes, tuning fork) is essential.
In diagnosing a breakthrough in cancer pain, first is necessary to ask the 
patient to describe his/her baseline pain over 24 hours, including description of 
location, intensity, quality, and other features. If continuous pain has fluctua-
tions and breakthrough pain suspected, it is necessary to ask the patient how 
many different types of breakthrough pains the patient experiences in a 24 hour 
period following pain variables: location, provocation, quality, etiology, etc. 
Finally, asking the patient about three most bothersome breakthrough pains 
allows us to determine what is a breakthrough pain really wearying the patient. 
Breakthrough pain intensity should be rated by NPS and filled in the pain 
diary. It also have to be investigated in detail including such characteristics as 
localization, number of episodes, possible irritant, beginning of pain outbreak, 
strength, quality, distribution, effectiveness of the medication used. It is also 
important to evaluate other symptoms of the patient’s pain breakthrough: 
psychological stress, spiritual suffering, craving for chemicals and medications, 
and cognitive function.
To conclude the evaluation of cancer pain, it is necessary to agree with the 
patient what the aim of the intended treatment is, what is the analgesia (score 
from…to), and what pain intensity is tolerated.
3.2 Challenges in cancer pain assessment
There are a number of significant challenges associated with the precise assess-
ment of a cancer patients’ pain [28]. They include: (1) multiple cancer pain mecha-
nisms, patients often have multiple coexiting pain disorders even in the one cancer 
as the example of breast cancer, pain can be caused by surgical outcome, tumor 
spread, chemotherapy and bony metastases to the spine, (2) lack of a universal 
cancer pain classification system, (3) lack of objective testing modalities, (4) time 
constraints of staff that failing in continuous reassessment of pain as this is a vital 
sign to be fully controlled, and (5) individual differences in cancer pain sensitivity.
Figure 1. 
Lithuanian pain scales (Decree of the Lithuanian MOH V-608, 26-08-2004 [27], English version).
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The National Cancer Institute (NIH, USA) has funded a Patient Reported 
Outcome Measurement System (PROMIS). This aims to develop a widely avail-
able set of standardized instruments to measure subjective outcomes in illnesses, 
including cancer [29].
4. Cancer pain treatment principles
Adequate pain relief can be achieved in 70–90% of patients when well-accepted 
treatment guidelines for cancer pain are followed (World Health Organization 
[30]). Therefore, pain management techniques should be implemented as early as 
possible to prevent the development of persistent pain, which can lead to a signifi-
cant reduction in quality of life. Unfortunately, the availability of effective therapy 
and updated guidelines from reliable leading societies has not eliminated the 
problem of undertreatment of cancer pain [3]. The causes of undertreatment are 
multifactorial and reflect the combined effects of clinician-, patient-, and system-
related barriers as been provided in this chapter previously (p.2, Introduction).
Methods of pain control in cancer pain can be divided into: (a) pharmacological, 
(b) oncological, (c) surgical, (d) interventional, (e) psychological, (f) physio-
therapy, and (g) complementary.
Medications are mainstream in the treatment of cancer pain and taken on a 
regular basis to provide pain relief. They are mostly given by oral administration 
as this increases ease of use and is usually the most cost-effective solution. Other 
forms of pain relief medication may be required in some cases, including rectal 
suppositories, transdermal patches, or injections.
The WHO analgesic ladder provides a structured starting point for the 
pharmacological treatment of the patient with cancer pain. It is not without 
controversy, however, some authors questioning the need to start all patients with 
severe pain on the bottom rung (i.e., managing with paracetamol alone rather 
than proceeding directly to stronger drugs). Some also have suggested that the 
second step (weak opioids) should be omitted in favor of low-dose strong opioids 
for the sake of both clinical effectiveness and simplicity [31]. For mild to moder-
ate cancer pain, simple analgesic medications such as paracetamol or nonsteroidal 
anti-inflammatory medications (e.g., ibuprofen or aspirin) can usually provide 
effective pain relief. Nevertheless, opioid analgesics are mainstream in treating 
the cancer pain as in most cases it is severe or even unbearable [32]. Some impor-
tant rules must be followed before starting with the prescription with opioids. 
Careful assessment of the pain and its effect on function, and of the possible risks 
associated with use of an opioid, are the first step. When opioids are considered, 
providers should assess every patient for risk factors for addiction. Providers 
should also employ strategies to reduce the risk of misuse for all patients who 
are taking opioids. These strategies may include urine testing, checking state 
prescription drug monitoring programs to evaluate a person’s history of filling 
prescriptions for controlled substances, doing pill counts, and using patient-
provider agreements or contracts.
Long-acting opioids may be administered orally or can be given in the form 
of a transdermal patch. Long-acting opioids are usually started at an initial low 
dose and titrated upward every 2–3 days for oral formulations and 5–6 days for 
patches. Short-acting opioid preparations may be used to treat breakthrough pain. 
One-sixth of the daily opioid requirement is commonly prescribed, and is often 
a useful starting point. Well-documented side-effects of opioid therapy include 
sedation, constipation, confusion, nausea and vomiting, pruritus, urinary reten-
tion, and occasionally, respiratory depression is necessary. Chronic administration 
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may lead to problems such as tolerance, physical dependence, and addiction. It 
must be noticed that by case, opioids may worsen pain—a phenomenon known as 
opioid-induced hyperalgesia. Management principles of side effects include: (a) 
opioid reduction or cessation, (b) opioid rotation, where one therapeutic opioid is 
substituted for an equivalent dose of another, (c) symptomatic treatment, and (d) 
administration of a specific antagonist.
Another group of pharmaceuticals used for the treatment of cancer pain is adju-
vants (Table 1). Common adjuvants are antidepressants, anticonvulsant, biphospho-
nates, and others [33]. An adjustment of adjuvants to the treatment plan of cancer pain 
is typical if the pain has a neuropathic element or is wholly neuropathic. In such cases, 
antidepressants and anticonvulsants may be more effective in providing balanced 
analgesia and better tolerance than the high doses of opioids. Bisphosphonates are 
helpful in reducing the severity of bone pain secondary to both osteoporotic vertebral 
collapse and metastatic deposit. They are incorporated into the structure of mineral-
ized bone as pyrophosphate analogues, to be then taken up by active osteoclasts, which 
are then inhibited. High-dose steroids can be given to reduce inflammation and edema 
associated with tumor growth, and to partially mitigate local mass effect. Capsular 
distension of intra-abdominal visceral can be very painful, and steroids may be help-
ful in this situation. They are also used for the immediate management of metastatic 
spinal cord compression and in the palliation of intracerebral lesions.
Chemotherapy, radiotherapy, endocrinotherapy, and immunotherapy are 
oncological methods used for cancer pain relief. Chemosensitive tumors include 
small-cell lung carcinoma, myeloma, colorectal, and breast cancers. These drugs are 
designed to target rapidly dividing cells, but can lead to the well-known side-effects 
of hair loss, mucositis, and diarrhea. Also, many chemotherapeutic agents are 
neurotoxic and cause varying degrees of temporary and permanent nerve damage, 
resulting in peripheral neuropathy.
Radiotherapy is particularly useful in the treatment of bony metastases and 
nonoperable pathological fractures, but may be used in various other contexts 
where the tumor type is known to be radiosensitive. Several types of radiotherapy 
exist: (a) localized external beam radiotherapy, (b) wide-field external beam 
radiotherapy, (c) brachytherapy, and (d) radioisotope treatment. Certain types of 
tumor may be dependent on circulating hormones to affect growth, and therefore 
susceptible to manipulation of the endocrine system, for example, prostate cancer. 
The use of immunotherapy in cancer treatment has shown to improve survival even 
in some advanced cancers, such as breast tumor.
Surgery can be undertaken with curative or palliative intent. If a cancerous 
tumor is responsible for causing the pain, techniques to reduce the size or obstruc-
tion of the tumor offer the greatest benefit. This may involve surgical removal of 
the tumor or shrinking of the tumor with radiation therapy. Neurosurgery to cut 
or block the nerves involved in the pain pathways can also help to reduce severe 
neuropathic pain. Bone fixation may be necessary to palliate a pathological fracture 
or decompress the spinal cord.
The aim of interventional cancer pain management is to interrupt nocicep-
tive transmission at one or more points between periphery and cortex to achieve 
adequate analgesia. This can be achieved via reversible, nondestructive techniques 
for diagnostic purposes and short-term analgesia, or offer a longer-lasting solution 
via the physical or chemical destruction of the nervous tissue.
The diagnosis of a life-threatening illness has a huge psychological impact on 
patients and their families. Grief reactions, anxiety, and depression are particularly 
problematic at nodal points in the cancer pathway: at diagnosis, starting treat-
ment, recurrence, failure of treatment, and facing the prospect of dying. Such 
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psychological states exacerbate, and also are exacerbated by, uncontrolled pain, and 
addressing them is often of paramount importance in beginning to manage pain 
and improve the quality of life. Multidisciplinary input, with the use of evidence-
based interventions such as cognitive behavioral therapy, distraction and relaxation 
techniques, graded exercise, and goal setting can be delivered with the involvement 
of psychologists, physiotherapists, and occupational therapists.
There are some complimentary medicinal techniques that can be used as addi-
tional complex in the treatment of cancer pain. These include: (a) acupuncture, 
which can help to relieve pain through the manipulation of pressure points in the 
body, (b) biofeedback is a technique that promotes awareness of bodily processes 
such as heart rate and blood pressure to influence the severity of the pain, (c) 
distraction techniques such as music therapy can be useful to shift attention away 
from the pain to a more pleasant stimulus, (d) hot or cold packs can be helpful 
to regulate pain and provide relief, (e) hypnosis can be used to manage pain by 
focusing the patient’s consciousness to process pain information more effectively, 
and (f) relaxation exercises can be used to refocus the attention of the patient on a 
specific task, such as breathing, to lessen the pain.
In general, an effective strategy for cancer pain management is predicated on 
several broad principles [34]:
• A detailed assessment of the pain should be performed initially; careful 
reassessment is indicated whenever a change occurs. The initial assessment 
of the patient with cancer pain always includes a history and examination, 
and often requires imaging or laboratory tests. The approach may be concep-
tualized as collecting data are sufficient to characterize key elements of the 
pain (a specific pain syndrome, the inferred pathophysiology, the etiology of 
pain, etc.).
• The second principle recognizes that pain may be addressed by disease-
modifying antineoplastic therapy and other interventions directed against 
the etiology of the pain. Treatments that address the underlying etiology of 
pain, such as radiation therapy, surgery, or in some cases, chemotherapy can 
be integrated into a broader plan of care for symptom control. Treatment 
of cancer-related pain usually requires close consultation with an oncology 
specialist, who can provide the necessary information about the availability 
of antineoplastic therapy.
• Whether or not primary disease-modifying therapy is possible, a large propor-
tion of patients with pain due to active cancer require symptomatic treatment. 
Beginning in the early 1980s, a worldwide consensus has evolved that consid-
ers opioid-based pharmacotherapy as the mainstay approach for the symptom-
atic treatment of cancer patients with active disease and pain that is moderate 
to severe. This conclusion was originally codified in the World Health 
Organization’s (WHO) “analgesic ladder” approach, which was originally 
published in the mid-1980s and has had a global influence on clinical practice 
and policies pertaining to medication availability.
5. WHO analgesic ladder in twenty-first century
In 1986, the World Health Organization (WHO) declared cancer pain manage-
ment algorithm, so called three-step analgesic ladder (Figure 2) [35].
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Figure 3. 
Modified WHO ladder approach for cancer pain (Fine P G, 2005).
I step: main medication—aspirin, acetaminophen, and nonsteroidal anti-
inflammatory drugs (NSAIDs) are used for the treatment of mild pain (score 1–3 in 
NAS). Nonopioids can be used as adjuvants in II and III steps analgesia.
II step: medication—weak opioids: codeine, dihydrocodeine, and tramadol are 
used for moderate intensity pain relief (4–6 by NAS). The upper tramadol daily 
(ceiling) dose is 400 mg. If oral or parental route of administration is not pos-
sible, for moderate pain treatment, one can use strong opioids in low doses, e.g., 
transdermal fentanyl patches.
III step: medication—strong opioids: morphine, fentanyl, methadone, and oth-
ers are used for severe and intolerable cancer pain (NAS-7-10) relief [36].
Adjuvants may be administered in all steps together with main analgesics. They 
enhance pain relief and decrease or prevent opioids side effects. In 2000, algorithm 
was revised in decreasing limitations of opioid use, enabling to start treatment with 
Figure 2. 
Cancer pain management—three step WHO analgesic “ladder” [35].
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strong opioids if patient is suffering from severe cancer pain. Other modifications 
of WHO three-step analgesic ladder were later applied (2005), introducing spinal 
opioids for refractory pain (see Figure 3).
6. Pharmaceuticals
There are two groups of medication for cancer pain management: (1) analgesics: 
opioids and nonopioids and (2) adjuvants.
6.1 Analgesics
Opioid analgesics are: (a) weak: tramadol, codeine (and dihydrocodeine) and 
(b) strong: morphine, fentanyl, methadone, buprenorphine, pethidine [37]. The 
route of administration are as follows: (a) noninvasive (oral, rectal, transdermal, 
nasal, sublingual), (b) invasive-parenteral (intramuscular, intravenous, subcutane-
ous, etc.), including long acting devices such as “morphine pumps “with subcutane-
ous or epidural catheters and PCA-patient-controlled analgesia option, allowing 
patient to determine and regulate the needed day and night doses of opioids. The 
day dose is determined by giving short-acting (immediate release) opioids, such as 
morphine hydrochloride 1% or morphine sulfate, 1–2% solution injections or tablets 
(e.g., 10 mg every 4 hours), day dose correction is made after 24–48 hours. After 
the needed day dosage is achieved (after 3–4 days), we switch to long-acting (slow 
release) (12–24 hours) morphine medication—tablets, suspension, suppositories, 
or fentanyl patches (72 hours) [38]. If morphine was administered parenterally, the 
needed daily oral or rectal dose of morphine should be three times bigger than the 
injected one earlier. Short-acting (immediate release) opioids should be used for 
breakthrough pain relief.
The use of opioid analgesics may induce [39]:
(a) tolerance—a state of adaptation in which exposure to a drug induces changes 
that result in diminution of one or more of the drugs’ effects over time, which 
is while using opioid, one has to increase its dose after some time due to the 
decrease in analgesic effect;
(b) physiologic dependence—a state of adaptation that is manifested by a drug-
class-specific withdrawal syndrome that can be produced by abrupt cessation, 
rapid dose reduction, decreasing blood level of the drug, and/or administration 
of an antagonist. It can be avoided by gradual opioid dose reduction;
(c) psychologic dependence (addiction)—a primary chronic, neurobiologic 
disease with genetic, psychosocial, and environmental factors influencing its 
development and manifestations. It is characterized by behavior that includes 
one or more of the following: impaired control over drug use, compulsive use, 
and continued use despite harm and craving (AAPM, APS, ASAM, 2001).
Adverse effects of opioids: constipation, nausea/vomiting, respiratory depres-
sion, urinary retention, pruritus, sedation, and more rarely, neurotoxic disorders-
hallucinations, seizures, delirium, hyperalgesia. To evade or decrease these effects, 
one uses adjuvants (laxatives, antiemetics) or opioid rotation (changing one strong 
opioid to another and adapting the dosage).
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6.2 Opioid rotation
Opioid rotation is a change of one opioid drug to another due to acquired toler-
ance or unmanageable side effects. These are the rules of opioid rotation:
• additional clinical assessment of pain and its diagnostics;
• adaptation of the day dosage for the newly prescribed opioid (in 24 hours period);
• determine the equianalgesic dose of the new opioid (Table 2);
• decrease the determined dose of newly applied opioid by 25–50% to avoid cross-
tolerance of both drugs and possible inadequacy of the dosage;
• if after applying new opioid, the pain relief is not enough and its dose is increased 
by 100–125%;
• titrate new drugs’ dose for 24 hours until good pain control is achieved;
• evaluate side effects and drugs’ effectivity; and
• pain re-assessment for every 2–3 days.
Opioid rotation is applied according to opioids equianalgesic doses table, thus 
changing the daily dose of the new drug [40].
In the event of opioid overdose antagonist, naloxone is applied.
The adequate pain control is achieved gradually, by dose titration and adminis-
tration of various treatment options. Preliminary period of time to achieve:
• no awakening at night due to pain—2–3 days;
• no pain while not in movement (seated or lying in bed)—3–5 days;
• no pain while moving—3–7 days (not for patients with multiple vertebral and 
pelvic bone metastases—for them total pain control may not be achieved); and
• for patients experiencing anxiety and depression—3–4 weeks.
Medication Route of administration Equivalent of 10 mg morphine dose
Codeine Oral 100 mg
Tramadol Oral/parenteral 50–100 mg/25–50 mg
Oxycodone Oral/parenteral 5–7.5 mg/3.33–5 mg
Pethidine Parenteral 25 mg
Methadone Oral 5 mg*
Fentanyl Patch 0.067 mg**
Morphine Parenteral 3.33–5 mg
*Methadone/morphine, if morphine day dose: (a) >30 mg 1:4, (b) >100 mg 1:8, and (c) >300 mg 12:1.
**Fentanyl/morphine, if morphine day dose: (a) 30 mg—12 mcg/hours, (b) 60 mg—25 mcg/hours, (c) 90 mg—37 
mcg/hours, (d) 120 mg—50 mcg/hours, etc.
Table 2. 
Opioid equianalgesic day doses.
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Nonopioids: aspirin, paracetamol, and nonsteroidal anti-inflammatory drugs 
(NSAIDs). They are effective in treating mild pain (score 1–3 by number analogue 
pain intensity scale (NAS)), due to bone metastases, soft tissue or muscular irrita-
tion, and damage. They are treating inflammation and decreasing fever and pain. 
NSAIDs are COX-1 and COX-2 also COX-3 inhibitors. They can be quite toxic to 
the GI tract (dyspepsia, erosions, ulcers, bleeding, constipation), slowing throm-
bocytes aggregation, impairing renal and liver function, enhancing hypervolemia, 
provoking rashes, headaches, dizziness, and allergic reactions. These drugs have 
their upper dose limit so-called “ceiling effect” when the analgesic effect cannot be 
increased but the adverse effects are progressing.
6.3 Adjuvant drugs
Glucocorticoids ( dexamethasone, prednisolone, hydrocortisone)—indica-
tions: increased intracranial pressure, spinal cord compression, nerve compres-
sion or infiltration, bone metastases, extended liver capsule, soft tissue cancer 
infiltration (head and neck, abdominal, and pelvic tumors). Contraindications: 
no absolute contraindications, dose is limited by adverse effects, and being 
cautious with peptic ulcers, diabetes, cardiovascular dysfunction, and endemic 
situations. Adverse effects: Cushing syndrome, gastric ulcers, erosions, bleed-
ing, increased appetite, weight, hyperglycemia, diabetes complications, muscle 
wasting, euphoria, dysphoria, emotional lability, depression, steroidal psychosis, 
edemas, hypertension, thrombosis, myopathies, decreased immunity to infec-
tions, potassium blood levels, liquid detention in the body, insomnia, skin 
purpura, etc.
Drugs for neuropathic pain: antidepressants, anticonvulsants, local anesthetics, 
and myorelaxants (baclofen).
Antidepressants—not always effective for neuropathic pain treatment and is 
better to prescribe tricyclic antidepressants (TCAs). Start with amitriptyline — 
10–25 mg dose in the evening and then increase to 50–100 mg/day. If no effec-
tive pain relief is achieved, it is discontinued after 1 week of use. Adverse effects: 
somnolence and hypotension.
Anticonvulsants—for neuropathic pain—gabapentin, carbamazepine, and 
clonazepam. The starting dose is the same as treating epilepsy. Increase until pain 
relief is achieved, or unmanageable adverse effects (nausea, vomiting, somnolence, 
ataxia, dizziness, disorientation) occur.
Local anesthetics (lidocaine, mexiletine)—for neuropathic pain systemic treat-
ment when other options are not working. Adverse effects: somnolence, nausea, 
tremor, dyspepsia (better use while eating).
NMDA receptors antagonists (ketamine)—for persistent neuropathic pain and 
other chronic pain when opioids are not tolerated. Routes of administration of 
ketamine: oral, intravenous, starting with 100 mg/day, and titration till 500 mg/
day. Adverse effects: psychomimetic can be reversed by benzodiazepines and 
haloperidol.
According to medical literature, about 20% of women have neuropathic pain 
after mastectomy and about 1/3 of cancer patients suffer from neuropathic pain (or 
both—nociceptive and neuropathic—together).
Bisphosphonates (pamidronate, zoledronic acid)—decrease bone resorption, 
effective in treating cancer hypercalcemia, decrease bone pain and occurrence of 
pathologic bone fractures for the patients with bone metastases, inhibit activity of 
osteoclasts, and are useful with ineffective radiotherapy and analgesics.
Radionuclides—Stroncium 89 systemic administration effectively relieves pain 
due to bone metastases, better works for osteoblastic metastases, and helps about 
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80% of patients. The response lasts from 3 to 6 months and is evident already after 
2–3 weeks. Adverse effects: myelosuppression, monitored by blood tests. Trials with 
radioisotopes of samarium and rhenium were also performed.
Psychotropic drugs—neuroleptics. Common neuroleptics (e.g., haloperidol) 
have no analgesic effect but decrease anxiety, insomnia, treat nausea, and delirium. 
Levopromazine has analgesic effect: 20 mg dose is equivalent to 10 mg of mor-
phine. Adverse effects: somnolence and hypotension. Benzodiazepines (diazepam, 
lorazepam, oxazepam) are useful for muscle spasms or acute bone-muscular 
pain. Adverse effects: hypotension, somnolence, and fatigue. Psychostimulants: 
metilphenidate has no analgesic effect and may be used to decrease severe opioid-
induced somnolence. Adverse effects: dysphoria, tolerance, and dependence.
Myorelaxants—baklofen (act on spinal cord level, start with 5 mg/day dose, and 
increase till 100 mg/day, for severe hiccup (hiccough)). Adverse effects: fatigue  
and somnolence. It should be discontinued slowly due to possible withdrawal syn-
drome and convulsions. Dantrolene—primary effect on muscles. Start with 25 mg/
day, and continue with maximal titration till 400 mg/day. Adverse effects: fatigue, 
somnolence, and hepatotoxicity.
7. Invasive cancer pain management
In most patients, cancer pain can be adequately controlled with pain medica-
tion; however, in 5–14% of oncological patients’, invasive pain management is 
needed [41]. Invasive procedures are the part of the option available for cancer 
pain management. Anesthetic, neurosurgical, or other invasive procedures can be 
given. Interventional pain management can improve pain control and reduce the 
amount of systemically administered drugs and their side effects. Also, invasive 
procedures can be an option when it is not possible to administer oral or parenteral 
medications. Final decision maker is a physician (anesthetist, pain specialist, and 
neurosurgeon) who will perform the procedure. He is main person that will decide 
about indications and contraindications for intervention treatment and will explain 
and talk with the patient or his relatives about the possibility of intervention and of 
course risk factors and possible complications. Invasive cancer pain procedures can 
be divided in to nondestructive and destructive.
Nondestructive procedures are such that the pain signal is modulated or inter-
rupted (blocked) by the administration of a pharmacological agent to a source of 
pain. The pharmacological preparation may be administered by a single shot dose or 
via a catheter for long-term administration of the medication. Usually, the catheter 
is placed neuroaxially (into the spinal canal) or near the peripheral nerves or plex-
uses. Peripheral nerve blocks/injections can be used, but they are effective for short 
term and are usually performed in patients with limited survival when the pain 
source is one or more nerves or when the pain is caused by pathological fractures or 
vascular occlusion. As a first-line treatment, these blockades are rarely used and, if 
applicable, it is necessary to combine with systemic analgesics.
Neuraxial invasive procedures can be: intrathecal or epidural. For example, an 
epidural medication injection (transforaminal or translaminar) or catheter/devise 
placement is applied in most of the cases when the nerve structures are involved in 
pain cause.
In case of complicated cases and intolerable pain, opioid analgesics can also be 
delivered through neuraxial delivery systems. The use of neuraxial system for long 
term can range from simple percutaneous (tunneled) patient controlled to implant-
able complex programmable medication delivery systems. Implantable systems are 
expensive, but safe and their application is always justified, if patient need pain 
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control longer than 3 months and other medical treatments are not effective [42, 
43]. These techniques may be on an oncological pain management plan, but they do 
not generally apply to everyday cases.
Destructive procedures can be applied in cases where pharmacological prepara-
tions cannot modulate the pain signal. For example, in case of small cell lung cancer 
and mesothelioma, chest pain is poorly localized, severe, and intolerable. This is 
because intercostal nerves and their branches can be infiltrated in cancer cells, dur-
ing metastatic spread and making it difficult to manage the source of pain. Then, 
the cordotomy can be applied—a neurosurgical procedure in which the spinal cord-
spinothalamic tract ablation is performed in the area opposite to the pain. After the 
ablation pain disappears, but along with the disappearing of pain on the part of the 
body below, the ablation area develops temperature and paresthesia [44]. Another 
destructive procedure is rhizotomy, segmental or multisegmental destruction of 
spinal cord nerve roots. It can be done in several ways: (a) surgically, (b) chemical 
neurolysis (phenol), and (c) radio-frequency ablation [45, 46].
Chemical neurolysis is widely used in the treatment of intractable cancer-related 
pain, especially in abdominal and pelvic cancer-related pain. These procedures can 
provide prolonged pain relief (3–6 month) and decrease the need of opioids.
High evidence is for coeliac plexus neurolysis in pancreatic cancer-related 
pain [47].
Neurolytic agents that often used for chemical neurolysis are alcohol, phenol, 
and glycerol.
All procedures can be done under ultrasound, X-ray, or CT scan. After the 
procedure, patient may experience significant pain relief and opioid withdrawal 
symptoms [48].
8. Nonpharmacological cancer pain treatment
Palliative radiotherapy is effective for the treatment of cancer pain caused by 
bone and brain metastases, metastatic skin ulcerations, and infiltrative growth 
of tumor in soft tissues. The summary dose of palliative radiotherapy is smaller 
than the dose for radical radiotherapy; maximal effect is achieved giving minimal 
number of radiation fractions (1–5) [49].
Transcutaneous electroneurostimulation (TENS)-nerve stimulation via elec-
trodes put on skin, thus, inhibits pain signal in spinal cord. Optimal dose varies for 
different patients. TENS is used for the treatment of mild and moderate cancer pain 
but is not effective for visceral pain. TENS is contraindicated for the patients with 
pacemaker (ECS). Pain relief effect is quick but usually not long-lasting (only for 
15–20% of patients).
Psychotherapy-introducing patients psychological support groups, delivering 
enough information; relaxation therapies, meditation; cognitive therapy, auto-
training, hypnosis, short psychotherapy seances with psychotherapist. Drug is 
administered if there is a need to correct renal, liver failure, and antidepressants 
for depression [50].
Acupuncture, physical therapy, mild massage can also be applied.
9. Cancer pain and palliative care
Palliative care includes palliative cancer treatment options, such as palliative 
radio therapy, palliative surgery, palliative chemotherapy, also pain relief and 
control of other symptoms caused by advanced cancer [51].
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Figure 4. 
Palliative care models (WHO directives, 2002) (adapted by Skorupskiene (2018)).
Palliative surgical procedures—palliative operations such as tumor mass reduc-
tion, stomas: colostomy, tracheostomy, gastrostomy, nephrostomy, etc., and drain-
age of pleural effusion and ascites.
Palliative chemotherapy is effective while treating pain, caused by chemotherapy-
susceptible tumor and metastases. The main goal is to minimize its side-effects. 
Monotherapy of drug combination in reduced doses can be applied [52].
Most common symptoms control [53].
Anorexia is a loss of appetite, usually with decreased food intake. Cachexia-lack 
of nutrition and wasting. Causes maybe disease-related (bowel obstruction, etc.), 
psychological or treatment-related (intoxication due to chemotherapy, radiation 
esophagitis, etc.). Treatment-dietary consultation, parental/enteral nutrition, 
medications (e.g., megestrol acetate suspension), odor control, and counseling.
Constipation is a common symptom in palliative care. The key should be prevention. 
Causes can be diseases related to GI obstruction, neurologic (spinal cord compression), 
hypercalcemia, inactivity; or treatment related-opioids, other medication. Treatment-
laxatives, other medication, increasing fluid intake, and dietary consultation.
Nausea and vomiting—common in advanced disease. Assessment of etiology is 
important, maybe acute, anticipatory (e.g. before chemotherapy) and delayed. Causes 
can be physiological (GI pathology, metabolic dysfunction, brain metastases, also-
treatment related (opioids), psychological. Treatment—both pharmacological (anti-
cholinergics, antihistamines, steroids, prokinetic agents, etc.) and non-drug treatment 
(small/slow feeding, dietary consultation, relaxation/distraction techniques).
Lymphedema—chronic, progressive swelling due to failure of lymph drainage. 
Patients limbs and whole body can be affected. Treatment—skin care, compression, 
limb elevation, education, etc. For those patients trophic ulcers and bedsores occur 
more often.
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Advanced cancer patients at the end of life also often exhibit delirium (acute 
change in cognition/awareness) with agitation and confusion (disorientation, inap-
propriate behavior, hallucinations). The causes vary, most common-medications, 
infection, bladder distention, hypoxemia. As treatment option medication re-
evaluation, hydration, oxygen therapy, reorientation, psychotropic drugs should 
be considered.
Aging population and increasing number of long time cancer survivors, some of 
them finally ending as advanced cancer patients, now especially increase the need 
of hospice and palliative care [54]. It should be patient-oriented, and not related 
to artificial prolongation of life and failure to acknowledge the limits of medicine 
with inappropriate use of aggressive curative treatment. Palliative care should 
help with all patients’ problems (physical, psychological, social, spiritual), include 
interdisciplinary team approach (doctors, nurses, social workers, psychologists, 
other specialists and volunteers) and is oriented to achieve better quality of life for 
the patient and his/her family members. Palliative care should start for the cancer 
patients still receiving specific anti-cancer therapies, not waiting until all treatment 
options are exhausted (Figure 4).
General principles of palliative care:
1. patient and family as unit of care;
2. attention to physical, psychological, social, and spiritual needs;
3. interdisciplinary team approach;
4. education and support of patient and family;
5. extends across illnesses and settings; and
6. bereavement support [55].
The main idea of palliative care-no matter how much the disease is advanced, 
and what complex treatment has been applied, one always can do something more 
to improve the quality of life, still left for the patient.
10. Cancer basic pain relief
Planning pain relief for cancer pain patients one should take into the consider-
ation possible mechanisms and types of pain (nociceptive, neuropathic, mixed), 
patients’ wishes, former treatment. If psychological distress is present, talking 
about pain assessment is needed, if there is suffering, help from the clergymen 
may be useful. If the signs of drug addiction appear, drug release should be more 
controlled, physical aspects of pain relief introduced. With cognitive disorders 
depression and anxiety should be treated, also opioid rotation should be available.
Basic pain Breakthrough pain
Start—slow, gradual increase in intensity Start—acute, not predictable
Duration—no less 12 hours/day Duration—from several seconds to 30 minutes
Type—dull, pressing, gnawing… Type—acute, shooting, irradiating
Treatment—long acting, slow release opioids, 
fixed scheme
Treatment—short acting, immediate release opioids, on 
demand basis
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Cancer pain treatment algorithm [2]:
1. assessment of pain reason, type, and intensity;
2. pharmacological pain treatment: basic pain relief, breakthrough pain relief, 
and adjuvants;
3. nonpharmacological treatment of pain;
4. evaluation of results and correction of treatment plan; and
5. providing constant pain relief and palliative care.
10.1 Basic cancer pain drug treatment principles
After the cause and type of cancer pain is determined, the constant analgesia 
is started by the easiest route, the patient-oral or transdermal, individualizing the 
dose, and also providing drugs for relief from other symptoms. The drug is selected 
taking into consideration the type and intensity of pain, WHO “analgesic ladder,”, 
also drug combinations, but combined medications should not be used and no 
placebo drugs as well [56].
To prevent pain becoming chronic, cancer pain relief should be started as 
soon as pain appears, as it helps to reduce drugs doses, adverse effects, and 
achieve better drug tolerance. It also reduces the cost of pain treatment, enhances 
the trust between patient and doctor, and patient is socially active for a lon-
ger time. The pain relief effect should be quick, so we can start with stronger 
medications and later pass on the weaker ones. Different medication is used for 
different types of pain: (a) nociceptive pain, due to soft tissue, bone damage, 
and visceral pain are treated by combinations of nonopioids and opioids and (b) 
neuropathic pain, due to nerve compression—by opioids, glucocorticoids, when 
nerve is damaged—by antidepressants, anticonvulsants, and NMDA receptor 
antagonists [57].
11. Cancer breakthrough pain management
Breakthrough cancer pain (BTCP) is a transient exacerbation of pain that occurs 
either spontaneously or in relation to a specific predictable or unpredictable trigger, 
despite relatively stable and adequately controlled background pain [58]. The 
frequency is less than four times/day, if it takes more than four times/day, we need 
to think about lack in background cancer pain control.
Leading doctor in BTCP management should preform regular assessments and 
repeatedly investigate pain management after 1–4 weeks dependably on patient’s 
complexity.
It is important to understand that the BTCP management is different compared 
with background cancer pain, which is managed according to the ladder and “by 
the clock,” while for BTCP, “rescue medication” should be given as needed. Main 
feature is that the breakthrough cancer pain should be started when background 
cancer pain is well controlled (Figure 5) [59]. This type of pain can take about from 
30 minutes but not more than 60 minutes. The highest intensity of the pain can be 
reached at tenth minute, and it can take 1–4 episodes/day [60]. For that reason, for 
BTCP should be given very strong, short-acting opioids.
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It is better to use the same chemical opioid structure, which is chosen to manage 
background cancer pain.
When fentanyl plasters/patches is used, the short-acting medication (buccal or 
sublingual tablet) for BTCP control can be prescribed. The dose should be titrated 
up to effective one, because of the lipophilic structure and the absorption, which 
is through the mucous of the mouth and gastrointestinal tract. There is a variety 
of short-acting fentanyl forms (Table 3). For example, BTCP management can be 
started with 200 μg of oral transmucosal fentanyl citrate tablet or 100 μg buccal-
soluble film [61].
If for BTP management, immediate-release morphine is chosen, usually one BTP 
episode is needed, part of 1/6 injecting medication of all morphine day dose. Their 
pharmacokinetic characteristics have limitations, with a relatively slow onset of 
action (30–45 minutes) and duration of action of up to 4–6 hours [62].
BTCP management consists of other approaches as setting of pain management 
goals, education of the patient, and depending on the cause of breakthrough pain, 
occupational therapist, physiotherapist can be involved. Other acute causes as 
Formulation Description
Nasal spray Phosphate-buffered solution
Fentanyl pectin intranasal spray
Sublingual Sublingual fentanyl orally disintegrating tablet
Sublingual fentanyl tablet
Oromucosal Oral transmucosal fentanyl citrate
Buccal tablet Effervescent formulation
Buccal soluble film Fentanyl buccal soluble film
Table 3. 
Fentanyl short acting formulations.
Figure 5. 
Association of Palliative Medicine of Great Britain and Ireland (APM) algorithm for assessing breakthrough 
cancer pain.
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bone fractures, bowel perforation, etc. should be excluded, and if the BTCP can be 
predicted, pain medication should be given before the coming pain event.
The evaluation of the effectiveness of the pharmacological treatment of BTCP 
has a four-factor rule [63]:
1. pain relief;
2. day activity;
3. adverse effect of medications; and
4. possible inappropriate use of opioids.
Possible inappropriate use of opioids is very important factor in pain manage-
ment, and it should be carefully investigated. It manifests as addiction or pseudoad-
diction for strong opioids and can be associated with mental disease. Clinically, it 
can be seen as seeking for opioids and/or problematic opioid use. In order to correct 
the possible misconduct in the use of opioids, it is important that these require-
ments are met before they are given:
1. to distinguish between people with risk factors (drug users, alcohol dependent, 
gambling, having mental problems); and
2. modifying the use of drugs for the prevention of BTCP (by giving a slightly 
higher dose of slow-release opioid to relieve background pain, try to use nonopi-
oids for BTCP reduction, and family support-controlled home care, etc.) [64].
12. Cancer pain treatment for children and elderly patients
While treating cancer pain in children and elder patients, one should take into 
consideration the differences in metabolism, concurrent diseases. Children receive 
different adapted opioid doses, and opioid rotation is also different (e.g., better pain 
relief with methadone and not morphine).
Elderly patients more easily overdose opioids; one cannot double their opioid 
dose quickly for them. Also, one should be aware of elder persons’ liver and renal 
function; if there is some failure, the correction is essential before prescribing opioid 
medication. There are usually a lot of tablets and other oral drugs prescribed for 
the concurrent diseases, so there is necessary to determine daily opioid dosage very 
carefully.
13. Cancer survivors pain treatment
Chronic pain can be a serious, negative consequence of surviving cancer. As a 
result of remarkable advances in cancer diagnosis and therapy, today there are a 
record 14 million cancer survivors in the United States. However, an estimated 40% 
of survivors continue to experience persistent pain as a result of treatment, which 
can be detrimental to their quality of life [3]. Two-thirds of these individuals are 
surviving more than 5 years after diagnosis, supporting the need to study pain in this 
growing population [65]. National Cancer Institute’s Office of Cancer Survivorship 
characterizes the survivor as a person with a history of cancer who is beyond the acute 
diagnosis and treatment phase. Risk factors for chronic pain in survivors include the 
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type and invasiveness of the tumor, the treatment regimen used, the time since the 
cancer treatment has started, and the efficacy of initial pain therapy. Continuous pain 
is associated with impaired quality of life in this population [66]. As the population 
of cancer survivors expands, all clinicians, including oncologists, advanced practice 
providers, and primary care physicians who interact with these individuals, will 
require the knowledge and skills to implement best practices in the management of 
chronic pain. When analgesic drugs are used, the imperative to prescribe safely must 
expand beyond immediate adverse effects, such as the resulting respiratory depres-
sion or constipation associated with opioids, to incorporate awareness and mitigation 
of the long-term consequences of these and other analgesic agents.
Clinical practice guidelines are issued recently, and they deal comprehensively 
with the pain people experience after cancer treatment, and are unique in its focus 
on chronic pain among cancer survivors. Key guideline recommendations include: 
(1) clinicians should screen for pain at each encounter with a patient. Recurrent 
disease, second malignancy, or late onset treatment effects should be evaluated, 
treated, and monitored; (2) clinicians may prescribe nonpharmacologic interven-
tions such as physical medicine and rehabilitation, integrative therapies  
(e.g., acupuncture and massage), interventional therapies, and psychological 
approaches (e.g., guided imagery, hypnosis, and meditation); (3) systemic nono-
pioid analgesics (NSAIDS, acetaminophen) and adjuvant analgesics (selected 
antidepressants and anticonvulsants), may be prescribed to relieve chronic pain 
and/or improve physical function; (4) clinicians may prescribe a trial of opioids in 
carefully selected cancer patients who do not respond to more conservative pain 
management and who continue to experience pain-related distress or impairment 
of physical function [67]. The management of cancer survivors suffering chronic 
pain requires greater consideration of a multimodality plan of care that balances 
pharmacologic and nonpharmacologic techniques and may necessitate the involve-
ment of an interdisciplinary team; the goals of treatment in these populations may 
focus on improving function and limiting the long-term adverse effects of pain and 
of its treatment, as much or more as they do on improving comfort [68].
As therapeutic treatment options and outcomes improve, patients with cancer 
are living longer. Chronic pain can develop from a variety of sources: peripheral 
neuropathy, muscle or bone pain, surgery, radiation, and other conditions. 
Comorbidity with other conditions or syndromes can make assessing chronic pain 
more difficult. Different chronic pain syndromes may be present for cancer survi-
vors. Chronic inflammatory polyneuropathy is one of many well-recognized pain 
disorders, together with other treatment-related pain syndromes, such as postsur-
gical and postradiation pain. Hormonal therapies, such as aromatase inhibitors, 
can produce arthralgias. As the use of hematopoietic stem-cell transplantation 
expands, graft-versus-host disease (GVHD) is seen with greater frequency, 
leading to pain syndromes that can affect almost any organ system. In addition, 
immunosuppressive agents used to treat GVHD can lead to painful complications 
(e.g., corticosteroids and avascular necrosis). The recent validation of a tool spe-
cific to musculoskeletal symptoms in hematopoietic stem cell transplantation will 
allow better characterization of this painful phenomenon [69–71]. The important 
consideration when designing an usage of analgesics is the potential for harm, 
and drug-drug interactions with cancer therapies, or other treatments should 
be considered. Cytochrome P450 CYP 3A and CYP2D6 inhibitors can increase 
concentrations of opioids, such as codeine, oxycodone, hydrocodone, fentanyl, 
tramadol, and methadone, metabolized by this system [72, 73]. Methadone and 
buprenorphine can prolong the QT interval, an effect that can be potentiated by 
many chemotherapeutic agents, notably doxorubicin [74]. If pain is severe and 
disabling, and long-term opioid therapy is being considered, the potential for 
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opioid-related harm over time must also be evaluated. Persistent adverse effects 
such as constipation are well recognized, and risk of sleep-disordered breathing 
suggests that these conditions must be considered when opioid therapy is initi-
ated and later during the course of treatment. The potential for neurotoxicities, 
such as persistent mental clouding, increased risk of falls in the elderly, and other 
phenomena may occur. Opioid-induced hyperalgesia is well described in preclini-
cal models but has uncertain clinical importance; the potential is considered 
when a patient reports escalating pain in tandem with opioid dose escalation in 
the absence of identifiable worsening of a pain cause. Opioid-related harm may 
also result from misuse or abuse, the development of opioid addiction, or the 
occurrence of drug diversion within the community. The problem of prescription 
drug abuse is serious, leading to an increase in opioid-related deaths [75]. The 
treatment of patients with additional chronic conditions, a situation in which the 
patient may have two or more such conditions, referred to as multiple chronic 
conditions, is challenging. Insomnia and psychological distress are common 
conditions in patients with chronic pain, present in 17–90% of adult sufferers, 
respectively. The most common psychiatric disorders comorbid with chronic pain 
include depression, anxiety, personality disorders, and PTSD [76]. Evidence also 
suggests that patients with comorbid conditions are less likely to improve with 
standard chronic pain treatment [77].
Because cancer posttreatment pain is so complicated; good communication 
between patients and their medical providers is essential. Cancer survivors may have 
varying capacities to deal with a great source of information that can sometimes be 
overwhelming. Some patients may even be reluctant to discuss their pain, seeing it 
as a sign of weakness or fearing a recurrence; some may see it as an expected and 
untreatable complication of their cancer treatment. That is why a pain assessment 
is recommended at every visit. In teasing out how they are coping, clinicians need 
to ask patients how chronic pain is affecting them and suggest how they can work 
together to better manage their symptoms and improve their quality of life. The 
question arises regarding who should provide pain management for the cancer 
survivor: the oncologist and his or her team, the patient’s primary care provider, a 
multidisciplinary pain service, or any other professional? Oncology teams provid-
ing ongoing care for cancer survivors may be the optimal group to address pain, 
because they routinely manage a complex regimen of cancer therapies and related 
symptoms.
Comprehensive assessment, including the impact of pain on function and quality 
of life, is warranted for all survivors. Long-term assessment is also needed after 
clinical trials to better recognize novel or previously unrecognized painful conse-
quences of treatment, including those syndromes that may occur after treatment is 
completed. Carefully designed, extended studies of pharmacologic and nonphar-
macologic interventions to relieve pain and improve function are indicated in this 
population. An especially relevant and urgent need is research identifying those 
cancer survivors who respond optimally to opioid therapy and those at greatest risk 
of adverse effects.
14. General practitioner’s role
Cancer care generally requires the technical knowledge and skills of specialty 
physicians such as medical oncologists, surgeons, and radiation oncologists. 
General practitioners (GP) may play an essential role because they are often the 
initial point of contact for patients in obtaining screening or evaluating symptoms, 
and they may make referrals, coordinate care, and manage symptoms or comorbid 
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conditions. One of the main role for GP also is counseling cancer patients about 
treatment options and monitoring treatment progress and side effects [78].
The roles of GP’s for patients with cancer such as managing comorbid condi-
tions, chronic pain, or depression, and referring patients to hospice were tested 
in the study and showed that 22% of GPs reported no direct involvement in 
cancer care roles, while 19% reported heavy involvement, and rural practice 
location was not associated with greater GP involvement in cancer care [79]. 
There is a gradual move toward shared care models with GPs playing a central 
role alongside other healthcare providers. In this context, it will be important to 
understand the factors influencing the involvement of GPs in cancer care and 
how to maximize their involvement throughout the spectrum of cancer care 
[80]. The studies also confirm that the great majority of GPs are familiar with the 
modern management of pain control problems commonly encountered in prac-
tice, but are less aware of the drug options available for less common situations, 
particularly the use of syringe drivers [81]. Fortunately, there is no evidence of a 
reluctance to start strong opioids for severe pain, as identified in previous works 
[82]. However, it is of concern that only minority of GPs still are suggesting 
immediate-release opioids for breakthrough pain, and laxatives or antiemetics 
when starting strong opioids, which is a recommended practice in community 
palliative care [83].
Most common mistakes in the treatment of cancer pain are as following:
• monotherapy (NSAIDs or opioid analgesics only);
• a prescription of slow release(SR)-form opioids for intake regime “as needed”;
• improper treatment of side effects caused by medicines;
• medicine for breakthrough pain is added in the situation where basic pain is not 
controlled sufficiently;
• pain breakthrough is not treated at all;
• adjuvants (antidepressants, anticonvulsants) and related medicine are not used; 
and
• with the prescription of opioids, behavioral aspects of patients are not evaluated.
A general practitioner, who has diagnosed pain in a cancer patient, starts 
treatment with analgesics. A ladder analgesia scheme is used. Opioids may even be 
prescribed for moderate pain, and if the pain is severe and unbearable, the opioid 
analgesic is the main remedy for pain relief. A sufficient daily dose for baseline 
(basic) analgesia should be achieved by increasing the dose (titration) of the 
product [84]. When titrating the product, the following rules should be used: (a) 
pain is controlled and there are no side effects—treatment to continue the cur-
rent dose, (b) pain is controlled, but there are side effects—reduce the dose of the 
product, (c) pain is uncontrolled and there are no side effects—increase the dose 
of the preparation, and (d) pain is uncontrolled, in case of side effects, change the 
medicine [85].
It goes without saying that controlling such a complex syndrome as cancer pain 
can lead to other problems that require the help and advice of the pain physician. 
Therefore, GP should refer the cancer patient to a pain clinic for a clear indication of 
the following cases (indications):
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• when initiating opioid analgesics, basic pain control is not achieved and there 
is an unadjusted side effect of the drug;
• failure to achieve control over cancer breakthrough pain in cases where basic 
pain is well controlled;
• the control of basic pain by an opioid analgesic becomes ineffective, a tolerance 
to the preparation is suspected, and it needs to be changed to another opioid 
analgesic (opioid rotation);
• pain must be controlled by combining the pharmaceutical treatment and 
invasive procedures (patient controlled analgesia, pain relief block);
• inappropriate behavior with opioid analgesics is identified or developing of 
psychological dependence on them is suspected;
• repeated multidisciplinary pain assessment and specialized control (special-
ists’ meeting) is necessary; and
• if a cancer patient is given a palliative care nursing home or nursing home and 
cannot physically access the pain clinic, according to the above indications, the 
pain clinic staff can consult on arrival at the place of destination.
15. Conclusion
Following the International Association for the Study of Pain cancer pain is 
“unpleasant sensory and emotional experience associate with actual or potential 
tissue damage resulting either from the treatment of cancer or the cancer itself.” 
Due to the complexity of symptoms and multimodality of treatments, cancer pain 
is built in the most sophisticated field of medicine, where each patient’s stage of 
disease and diagnosis will require an individualized pain treatment plan to opti-
mize the quality of life. Such tasks can only be carried out using multidisciplinary 
approach. That is why basic knowledge about cancer pain is essential for every 
healthcare professional. We believe that the text you have just read will help you to 
be an active practitioner giving the patients the cancer pain relief.
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